Rivaroxaban also decreased the possibility for total venous thromboembolism or all trigger death also as for significant venous thromboembolism or venous thromboembolism relevant death.In contrast with enoxaparin, dabigatran was not connected to a unique risk of symptomatic deep vein thrombosis or pulmonary embolism.Dabigatran was related to a trend in the direction of a higher danger of complete venous thromboembolism or all result in death than enoxaparin and a equivalent possibility of serious venous thromboembolism or venous thromboembolism connected death.The threat of complete venous thromboembolism or all result in death was related among dabigatran 220 mg and enoxaparin nonetheless it was higher with all the dabigatran 150 mg dose than with enoxaparin.
Major venous thromboembolism or venous thromboembolism related death did not differ drastically in between the dabigatran 220 mg day by day dose v enoxaparin or among the dabigatran 150 mg each day dose v enoxaparin.Apixaban decreased the chance of symptomatic deep vein thrombosis in contrast with enoxaparin but was connected to a numerical improve in circumstances of pulmonary Iressa embolism with borderline heterogeneity.The outcomes for pulmonary embolism had been homogeneous inside of the two pivotal studies on complete knee substitute surgical procedure , during which the possibility of symptomatic pulmonary embolism with apixaban was significantly increased than that with enoxaparin.About the contrary, apixaban was related to a reduce danger of total venous thromboembolism or all trigger death along with a trend in the direction of a decrease danger of main venous thromboembolism or venous thromboembolism connected death than enoxaparin..
Primary safety end result Rivaroxaban was related mg132 that has a considerable expand in possibility of clinically pertinent bleeding.Dabigatran did not present a substantial boost in contrast with enoxaparin.The chance was equivalent inside the comparison of dabigatran 220 mg with enoxaparin and dabigatran 150 mg with enoxaparin.Around the contrary, apixaban was related to a drastically diminished risk of clinically pertinent bleeding compared with enoxaparin.No proof of statistical heterogeneity was found for this end result amid research comparing rivaroxaban, dabigatran, or apixaban with enoxaparin.Secondary safety outcomes Rivaroxaban was linked to a non-significant trend in the direction of a higher chance of serious bleeding than was enoxaparin and clinically relevant non-major bleeding.
Compared with enoxaparin, dabigatran was connected to a similar threat of big bleeding in addition to a non-significant trend in direction of a higher chance of clinically related non-major bleeding.Apixaban showed a non-significant trend in direction of a low chance of leading bleeding than did enoxaparin , which was within the limit of statistical significance for clinically relevant non-major bleeding.No sizeable trends have been uncovered in chance of death involving the new anticoagulants and enoxaparin.